Isaiah Frank, Desmond Fitzpatrick, Anders J. Carlherg,
... Mr D Investment advice Down on the Farm Geico Banco De Bilbao The Bowater Corporation Limited Key ...
1976 - Gale Group | The Economist
Ana Oaknin, D. Roda, Antonio González‐Martín, Luis Chiva, Jesús García-Donás, Ana De Juan, Andrés Redondo, Sergio Muñoz Martínez, Yolanda García García, Sílvia Catot, Jordi Ponce, José María del Campo, Andrés Cervantes, Andrés Poveda,
... from Institutions of the Spanish Ovarian Cancer Group (GEICO) were treated with a modified outpatient IP chemotherapy ... homogenize the IP administration and supportive measures, a GEICO guideline for IP chemotherapy was established. Patients were ... and gastrointestinal events (12 patients; 26%). Conclusions: The GEICO outpatient modified regimen resulted in a lesser toxicity ...
Tópico(s): Testicular diseases and treatments
2011 - BMJ | International Journal of Gynecological Cancer
Antonio González‐Martín, Andrés Redondo, M. Jurado, A. De Juan, Ignacio Romero, Isabel Bover, Josep M. del Campo, Andrés Cervantes, Yolanda García García, José Antonio López‐Guerrero, C. Mendiola, José Palacios, María Jesús Rubio, A. Poveda Velasco,
... Spanish Research Group for Ovarian Cancer (Spanish initials GEICO), the first “Treatment Guidelines in Ovarian Cancer” were ... this objective, a group of investigators of the GEICO group met in February 2012. This study summarizes ...
Tópico(s): BRCA gene mutations in cancer
2013 - Springer Science+Business Media | Clinical & Translational Oncology
... emergence of the caveman mythos, both in a Geico advertising campaign and an ABC television series, to ... the television series and gay stereotypes in the Geico ads to uncover a new process of hegemonic ...
Tópico(s): Media, Gender, and Advertising
2010 - Taylor & Francis | Communication Studies
Hope Ferdowsian, Neal D. Barnard, Valerie Hoover, Heather Katcher, Susan Levin, Amber A. Green, Joshua Cohen,
... study.Employees of the Government Employees Insurance Company (GEICO) (N = 113), aged 21 to 65 years, with ...
Tópico(s): Obesity and Health Practices
2010 - SAGE Publishing | American Journal of Health Promotion
Juan Francisco Grau-Béjar, Lorena Fariñas-Madrid, Ana Oaknin,
... the ENGOT umbrella alongside JGOG and GOG-F. GEICO is the lead group on behalf of ENGOT. ...
Tópico(s): Gastric Cancer Management and Outcomes
2019 - BMJ | International Journal of Gynecological Cancer
Antonio González‐Martín, Luisa Sánchez‐Lorenzo, Nicoletta Colombo, René dePont Christensen, Florian Heitz, Mihai Meirovitz, Frédèric Selle, Toon Van Gorp, Núria Álvarez, F. Javier Sánchez, Carmen Hernández Marqúes,
... and NIraparib Treatment Association (ANITA) trial is a GEICO (Grupo Español de Investigación en Cáncer de Ovario) ...
Tópico(s): Toxin Mechanisms and Immunotoxins
2021 - BMJ | International Journal of Gynecological Cancer
A. Yubero, Arantzazu Barquín, Purificación Estévez, Bella Pajares, Luisa Sánchez Brea, Piedad Reche, Jesús Damián Alarcón, Julia Calzas, Lydia Gaba, José Fuentes, Ana Santaballa, C. Salvador Coloma, Luís Manso, Ana Herrero, Álvaro Taus, Raúl Márquez, Julia Madani, Maria J. Merino, Gloria Marquina, Victoria Casado, Manuel Constenla, María Gutiérrez, Alba Dosil, Antonio González‐Martín,
... associated with the Spanish Ovarian Cancer Research Group (GEICO) recruited patients with high-grade epithelial ovarian, fallopian ...
Tópico(s): Toxin Mechanisms and Immunotoxins
2022 - BioMed Central | BMC Cancer
Joseph Calandro, Ranganna Dasari, Scott Lane,
... study of the 1995 Berkshire Hathaway acquisition of GEICO and draws on previously published Graham and Dodd methodological materials as well as GEICO's publicly available financial information. The valuation presented ... corporate M&A tool. The results of the GEICO case suggest that Graham and Dodd valuation could ... in the context of Berkshire Hathaway's 1995 GEICO acquisition. It demonstrates how that acquisition contained a ...
Tópico(s): Capital Investment and Risk Analysis
2007 - Emerald Publishing Limited | Strategy and Leadership
... such an opportunity is Warren Buffett’s 1995 GEICO acquisition. This article presents an approach for identifying, ... based franchise deals in the context of the GEICO case. The approach integrates strategic, financial, and performance ...
Tópico(s): Private Equity and Venture Capital
2011 - Euromoney Institutional Investor | The Journal of Private Equity
José Antonio López‐Guerrero, Marta Mendiola, José Alejandro Pérez Fidalgo, Ignacio Romero, Ana María Torres, D. Recalde, Elena Molina Roldán, César Gómez-Raposo, Ana M. Levín, Ana Herrero, Jesús Alarcón, Carmen Esteban, Gloria Marquina, María Jesús Rubio, Eva Guerra, Luisa Sánchez‐Lorenzo, Fernando Gálvez, Ana De Juan, Cristina Churruca, Alejandro Gallego, Antonio González‐Martín,
... oncology. The Spanish Group of Ovarian Cancer Research (GEICO), in collaboration with the Spanish Biobank Network (RNBB), ... collaboration between multicentre structures, promoted and supported by GEICO, that will contribute to the success of translational ...
Tópico(s): BRCA gene mutations in cancer
2022 - Multidisciplinary Digital Publishing Institute | Cancers
Beatriz Tavira, Teresa Iscar, Luís Manso, Ana Santaballa, Marta Gil-Martín, Yolanda García García, Margarita Romeo, María Iglesias, Ana de Juan Ferré, Maria-Pilar Barretina-Ginesta, Aránzazu Manzano, Lydia Gaba, María Jesús Rubio, Carlos E. de Andrea, Antonio González‐Martín,
... from 23 patients with ovarian cancer enrolled in GEICO 1205/NOVA clinical study before NACT and at ... not have an impact on PFS in the GEICO 1205 study. However, at the cellular level, changes ...
Tópico(s): Renal Diseases and Glomerulopathies
2023 - American Association for Cancer Research | Clinical Cancer Research
Ana Oaknin, María Iglesias, Jesús Alarcón, G. Villacampa Javierre, Laura García‐García, Ana Santaballa, Luís Manso, Ignacio Romero, M.P. Barretina Ginesta, Cristina Churruca, Yolanda García García, A.B. Sánchez, Gloria Marquina, Beatriz Pardo, Andrés Redondo, María Jesús Rubio, Antonio González‐Martín,
... open-label, multicenter, phase II trial led by GEICO Group evaluating dostarlimab as maintenance therapy in women ... Juan Luis Sanz (APICES) for his editorial assistance. GEICO (Grupo Español de Investigación en Cáncer de Ovario). ...
Tópico(s): Lymphoma Diagnosis and Treatment
2020 - Elsevier BV | Annals of Oncology
David Pizarro, Ignacio Romero, Belén Perez‐Mies, Andrés Redondo, Tamara Caniego-Casas, Irene Carretero‐Barrio, Eva Cristóbal, Ana Gutiérrez-Pecharromán, Ana Santaballa, Emanuela D’Angelo, David Hardisson, Begoña Vieites, Xavier Matías‐Guiu, Purificación Estévez, Eva Guerra, Jaime Prat, Andrés Poveda, José Antonio López‐Guerrero, José Palacios,
... from the Spanish Group of Ovarian Cancer Research (GEICO). Centralized histological typing was performed based on morphological ...
Tópico(s): Bladder and Urothelial Cancer Treatments
2023 - Multidisciplinary Digital Publishing Institute | International Journal of Molecular Sciences
Gema Bruixola, Santiago Domingo, Roberto Díaz, Javier Caballero‐Villarraso, Laura Palomar, Helena de la Cueva, Ana Santaballa,
... such as the Spanish Ovarian Cancer Research Group (GEICO) regimen, have been tested and have reported overall ... study was to assess the toxicity of the GEICO regimen in patients treated at our institution.We ... from June 2009 to April 2013 with the GEICO regimen. Patients received intravenous paclitaxel (175 mg/m2) ... were multifocal and extraperitoneal.The administration of the GEICO outpatient modified regimen was feasible with a good ...
Tópico(s): Endometrial and Cervical Cancer Treatments
2014 - BMJ | International Journal of Gynecological Cancer
Paul Hoskins, Ignace Vergote, Gavin Stuart, Andrés Cervantes, D. Tu, M. Carey, Diane Provencher, Dionyssios Katsaros, Prafull Ghatage, E. Eisenhauer,
LBA5505 Background: Topotecan was evaluated in a novel combination regimen in comparison to standard therapy in front-line EOC. Methods: Women with newly diagnosed EOC stages IIB-IV, ECOG PS 0–1, age ≤ 75, and were randomized to one of two q 21 day regimens. Arm 1 cycles 1 to 4: cisplatin 50 mg/m2 d1 plus topotecan 0.75 mg/m2 d1–5 IV; cycles 5 to 8: paclitaxel 175 mg/m2 over 3 hrs d1 followed by carboplatin AUC5 day 1. Arm 2 paclitaxel plus carboplatin as in Arm 1 for 8 cycles. Patients (pts) were ...
Tópico(s): Ovarian cancer diagnosis and treatment
2008 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Ana Oaknin, Antonio González‐Martín, Yolanda García García, Sílvia Catot, Cristina Caballero, Jesús García-Donás, Isabel Bover, Ana Santaballa, Eva Guerra, Beatriz Pardo, Laura Vidal, Raúl Márquez, Víctor Rodríguez-Freixinós, Ignacio Romero, Andrés Poveda,
5068 Background: Pazopanib (P) is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that inhibits angiogenesis. Signaling blockade of these pathways is associated with anti-tumor and anti- angiogenesis activity. Methods: Eligible patients (pts) had persistent or recurrent EOC/PPC /FTC up to 2 prior cytotoxic regimens. They had to have received at least a platinum–based line and fulfill platinum resistant criteria. Treatment consisted ...
Tópico(s): Gastric Cancer Management and Outcomes
2012 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Jalid Sehouli, Werner Meier, Pauline Wimberger, Radoslav Chekerov, Antje Belau, Sven� Mahner, Christian Kurzeder, Felix Hilpert, Peter Klare, Steffen Doerfel, Hans‐Georg Strauß, Ulrich Canzler, Christian Marth, Alexander Reinthaller, Edgar Petru, Rolf Richter, María Jesús Rubio, Isabel Bover, Antonio González‐Martín, Philipp Harter,
5031 Background: We present the efficacy data from a phase III study of topotecan (T) plus carboplatin (C) versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC). Methods: From 02/07 to 12/09, 590 pts were screened and 550 pts were randomized to either T (0.75mg/m²/d1-3/q21d) + C (AUC 5/d1/q21d) or to standard therapy with CP or GC or PLDC based on patient preference. Progression free survival at 1 year was defined ...
Tópico(s): Cancer Research and Treatments
2012 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Antonio González‐Martín, E. Calvo, Isabel Bover, María Jesús Rubio, Àngels Arcusa, Antonio Casado, B. Ojeda, Carmen Balañá, E Hortelano Martínez, Ana Herrero, Beatriz Pardo, Encarna Adrover, Juli Rifà, María José Godes, A Moyano, Andrés Cervantes,
BackgroundThe aim of this study was to determine whether the response rate for the paclitaxel–carboplatin combination is superior to carboplatin alone in the treatment of patients with platinum-sensitive recurrent ovarian carcinoma.Patients and methodsPatients with recurrent ovarian carcinoma, 6 months after treatment with a platinum-based regimen and with no more than two previous chemotherapy lines, were randomized to receive carboplatin area under the curve (AUC) 5 (arm A) or paclitaxel 175 mg/ ...
Tópico(s): Endometrial and Cervical Cancer Treatments
2005 - Elsevier BV | Annals of Oncology
Ulka Agarwal, Suruchi Mishra, Jia Xu, Susan Levin, Joseph F. Gonzales, Neal D. Barnard,
To determine whether a plant-based nutrition program in a multicenter, corporate setting improves depression, anxiety, and productivity.A quasi-experimental study examined the impact of diet on emotional well-being and productivity.The study was conducted in 10 corporate sites of a major U.S. insurance company.There were 292 participants (79.8% women, 20.2% men), with body mass index ≥25 kg/m(2) and/or previous diagnosis of type 2 diabetes.Either weekly instruction in following a vegan diet or no ...
Tópico(s): Child Nutrition and Feeding Issues
2014 - SAGE Publishing | American Journal of Health Promotion
Suruchi Mishra, Jia Xu, Ulka Agarwal, J Gonzales, Susan Levin, Neal D. Barnard,
To determine the effects of a low-fat plant-based diet program on anthropometric and biochemical measures in a multicenter corporate setting. Employees from 10 sites of a major US company with body mass index ⩾25 kg/m2 and/or previous diagnosis of type 2 diabetes were randomized to either follow a low-fat vegan diet, with weekly group support and work cafeteria options available, or make no diet changes for 18 weeks. Dietary intake, body weight, plasma lipid concentrations, blood pressure and glycated ...
Tópico(s): Nutritional Studies and Diet
2013 - Springer Nature | European Journal of Clinical Nutrition
Andrés Cervantes, Paul Hoskins, Ignace Vergote, Elizabeth A. Eisenhauer, Prafull Ghatage, Mark S. Carey, Dionyssios Katsaros, Andrés Poveda, Diane Provencher, Dongsheng Tu, Gavin Stuart,
5502 Background: Topotecan was evaluated in a novel combination regimen in comparison to standard therapy in front-line EOC. Methods: Women with newly diagnosed advanced EOC stages IIB-IV, ECOG performance status (PS) 0-1, age < 75, were randomized to either Arm 1: cycles 1 - 4: cisplatin 50 mg/m 2 d1 plus topotecan 0.75 mg/m 2 d1-5 IV; cycles 5 - 8: paclitaxel 175 mg/m 2 over 3 hrs d1 followed by carboplatin AUC5 day 1 or Arm 2: paclitaxel plus carboplatin as in Arm 1 for 8 cycles. The primary endpoint ...
Tópico(s): Cancer Research and Treatments
2013 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Paul Sabbatini, Philipp Harter, Giovanni Scambia, Jalid Sehouli, Werner Meier, Pauline Wimberger, Klaus Baumann, Christian Kurzeder, Barbara Schmalfeldt, David Cibula, Mariusz Bidziński, Antonio Casado, Andrea Martoni, Nicoletta Colombo, Robert W. Holloway, Luigi Selvaggi, Andrew Li, Jose Del Campo, Karel Cwiertka, Tamàs Pintér, Jan B. Vermorken, Éric Pujade-Lauraine, Simona Scartoni, Monica Bertolotti, Cecilia Simonelli, Angela Capriati, Carlo Alberto Maggi, Jonathan S. Berek, Jacobus Pfisterer,
To determine whether abagovomab maintenance therapy prolongs recurrence-free (RFS) and overall survival (OS) in patients with ovarian cancer in first clinical remission.Patients with International Federation of Gynecology and Obstetrics stage III to IV ovarian cancer in complete clinical remission after primary surgery and platinum- and taxane-based chemotherapy were randomly assigned at a ratio of 2:1 in a phase III, double-blind, placebo-controlled, multicenter study. Abagovomab 2 mg or placebo ...
Tópico(s): Viral-associated cancers and disorders
2013 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Suruchi Mishra, Neal D. Barnard, J Gonzales, Jin Xu, Ulka Agarwal, Susan Levin,
To assess the effects on macro- and micronutrient intake of a nutrition intervention program in corporate settings across the United States. Two hundred and ninety-two individuals who were overweight or had type 2 diabetes were recruited from 10 sites of a US insurance company. Two hundred and seventy-one participants completed baseline diet recalls, and 183 participants completed dietary recalls at 18 weeks. Sites were randomly assigned to an intervention group (five sites) or to a control group ( ...
Tópico(s): Obesity, Physical Activity, Diet
2013 - Springer Nature | European Journal of Clinical Nutrition
... the Gecko: Race, Sexual Orientation, and Marginality in GEICO's Cavemen Suggested Readings Index
Tópico(s): Rhetoric and Communication Studies
1995 - National Council of Teachers of English | College Composition and Communication
Yolanda García García, Ana De Juan, César Mendiola, Pilar Barretina-Ginesta, Laura Vidal, Ana Santaballa, Isabel Bover, Marta Gil-Martín, Aránzazu Manzano, María Jesús Rubio, Margarita Romeo, Alfonso Gómez De Liaño Lista, Elena García-Martínez, Antonio González‐Martín,
5531 Background: First-line carboplatin(C)-paclitaxel(P) and Bev has proved to be an active combination after primary debulking surgery and improved overall survival in suboptimal resected advanced EOC patients (pts). However, the role of Bev in the NA setting has not been well defined yet. Methods: We performed a phase II randomized open label multicentric study in 66 pts with high grade serous or endometroid EOC, FIGO stage III-IV, ECOG 0-2, considered unresectable in whom NA CT and interval debulking ...
Tópico(s): Renal cell carcinoma treatment
2015 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Jalid Sehouli, Radoslav Chekerov, Alexander Reinthaller, Rolf Richter, Antonio González‐Martín, Philipp Harter, Hannah Woopen, Edgar Petru, Lars Hanker, E. Keil, Pauline Wimberger, Peter Klare, Christian Kurzeder, Felix Hilpert, Antje Belau, Alain G. Zeimet, I. Bover-Barcelo, Ulrich Canzler, Sven� Mahner, Werner Meier,
Tópico(s): Testicular diseases and treatments
2016 - Elsevier BV | Annals of Oncology
Andrés Poveda, Ignacio Romero,
... created a need for national groups (such as GEICO in Spain) or even beyond that a need ...
Tópico(s): Cancer-related molecular mechanisms research
2016 - Elsevier BV | Annals of Oncology
Yolanda García García, Ana De Juan, César Mendiola, Maria Pilar Barretina-Ginesta, Aleix Prat, Ana Santaballa, Isabel Bover, Marta Gil-Martín, Aránzazu Manzano, María Jesús Rubio, Margarita Romeo, Cristina Arqueros, Elena García Martínez, Antonio González‐Martín,
5508 Background: First line carboplatin(C)-paclitaxel(P) and Bev has proved to be an active combination after primary debulking surgery and improve overall survival in sub-optimal resected advanced EOC patients (pts). However, the role of Bev in the NA setting has not been well defined yet. Methods: We performed a phase II randomized open label multicentric study in pts with high grade serous or endometrioid EOC, FIGO stage III-IV, ECOG 0-2, considered unresectable in whom NA CT and interval debulking ...
Tópico(s): Renal cell carcinoma treatment
2017 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Barbara J. Phillips, Jennifer R. Sedgewick, Adam D. Slobodzian,
From Mr. Peanut to the GEICO gecko, spokes-characters have been a consistently used promotional tool across time; previous research demonstrates that between the 1950s and 1990s, ...
Tópico(s): Digital Marketing and Social Media
2018 - Taylor & Francis | Journal of Current Issues & Research in Advertising